Fiche publication
Date publication
décembre 2010
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DELMAS Dominique
Tous les auteurs :
Tili E, Michaille JJ, Alder H, Volinia S, Delmas D, Latruffe N, Croce CM
Lien Pubmed
Résumé
Resveratrol (trans-3,4',5-trihydroxystilbene) is a natural antioxidant with cardiovascular and cancer preventive properties that is currently at the stage of pre-clinical studies for human cancer prevention. Beside its known effects on protein coding genes, one possible mechanism for resveratrol protective activities is by modulating the levels of non-coding RNAs. Here, we analyzed the effects of resveratrol on microRNA populations in human SW480 colon cancer cells. We establish that resveratrol treatment decreases the levels of several oncogenic microRNAs targeting genes encoding Dicer1, a cytoplasmic RNase III producing mature microRNAs from their immediate precursors, tumor-suppressor factors such as PDCD4 or PTEN, as well as key effectors of the TGFbeta signaling pathway, while increasing the levels of miR-663, a tumor-suppressor microRNA targeting TGFbeta1 transcripts. We also show that, while upregulating several components of the TGFbeta signaling pathway such as TGFbeta receptors type I (TGFbetaR1) and type II (TGFbetaR2), resveratrol decreases the transcriptional activity of SMADs, the main effectors of the canonical TGFbeta pathway. Our results establish that protective properties of resveratrol may arise at least in part from its capability to modify the composition of microRNA populations in cells, and suggest that the manipulation of the levels of key microRNAs, such as miR-663, may help to potentiate the anti-cancer and anti-metastatic effects of resveratrol.
Référence
Biochem Pharmacol. 2010 Dec 15;80(12):2057-65
